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ABSTRACT
RAD51, an essential eukaryotic DNA recombinase,
promotes homologous pairing and strand exchange
during homologous recombination and the recom-
binational repair of double strand breaks. Mutations
that up- or down-regulate RAD51 gene expression
have been identified in several tumors, suggesting
that inappropriate expression of the RAD51 activity
may cause tumorigenesis. To identify chemical
compounds that affect the RAD51 activity, in
the present study, we performed the RAD51-
mediated strand exchange assay in the presence
of 185 chemical compounds. We found that 4,
4’-diisothiocyanostilbene-2,2’-disulfonic acid (DIDS)
efficiently inhibited the RAD51-mediated strand
exchange. DIDS also inhibited the RAD51-mediated
homologous pairing in the absence of RPA. A sur-
face plasmon resonance analysis revealed that
DIDS directly binds to RAD51. A gel mobility shift
assay showed that DIDS significantly inhibited the
DNA-binding activity of RAD51. Therefore, DIDS
may bind near the DNA binding site(s) of RAD51
and compete with DNA for RAD51 binding.
INTRODUCTION
Genomic DNA is continuously under attack from exoge-
nous and endogenous mutagens, such as ionizing radia-
tion, oxygen-free radicals, DNA cross-linking reagents
and DNA replication failure. Such mutagens cause
double-strand breaks (DSBs), which induce chromosome
aberrations and tumorigenesis if they are not repaired
appropriately (1,2). Homologous recombinational repair
(HRR) is an accurate pathway for DSB repair without
base substitutions, deletions and insertions (3–5).
RAD51 is an essential protein for the HRR pathway
(6). The RAD51-gene knockout in mice results in early
embryonic lethality (7,8). In chicken DT40 cells, the
RAD51-knockout causes cell death, with the accumulation
of unrepaired DSBs (9). These facts indicated that RAD51
is actually required for DSB repair in higher eukaryotes.
Consistent with the importance of RAD51 in the
HRR pathway, mutations in the RAD51 gene have been
identiﬁed in several tumors (10–14). Most of the RAD51
mutations in tumor cells were found in its non-coding
region, suggesting that improper up- and down-regulation
of the RAD51 activity may be a source of tumorigenesis.
A missense RAD51 mutation, in which Arg150 is replaced
by Gln (R150Q), was also found in patients with bilateral
breast cancer (10,15). In addition, the Tyr315 residue of
RAD51 was found to be constitutively phosphorylated by
the BCR/ABL fusion protein, which is derived from the
translocation of the c-ABL gene from chromosome 9 to
the BCR gene locus on chromosome 22 (Philadelphia
chromosome) in leukemia patients (16). These ﬁndings
strongly suggest the involvement of the RAD51 activity
in tumorigenesis or tumor progression.
During HRR, RAD51 assembles onto single-stranded
DNA (ssDNA) tails, which are produced at the DSB
sites, and forms a helical ﬁlamentous polymer. This
RAD51-ssDNA ﬁlament then binds to intact double-
stranded DNA (dsDNA), and a nascent heteroduplex is
formed between the ssDNA and the complementary
strand of dsDNA within the ﬁlament (homologous pair-
ing). The heteroduplex region is then extended by RAD51
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RAD51-mediated recombination reactions, such as
homologous pairing and strand exchange, are the key
steps in DSB repair through the HRR pathway (17–21).
Therefore, alterations of the RAD51-mediated recom-
bination reactions by chemical compounds may result
in the suppression of tumorigenesis and/or tumor
progression.
To identify chemical compounds that regulate the
RAD51 recombinase activity, in the present study, we
screened 185 chemical compounds for their eﬀects
on RAD51-mediated strand exchange in vitro.W e
found that 4,40-diisothiocyanostilbene-2,20-disulfonic acid
(DIDS) eﬃciently inhibited the RAD51-mediated homol-
ogous pairing and strand-exchange reactions.
MATERIALS AND METHODS
Proteins
Hexahistidine-tagged human RAD51 was overexpressed
in the Escherichia coli strain JM109 (DE3), which also
carried an expression vector for the minor tRNAs
(Codon(+)RIL, Stratagene, La Jolla, CA, USA). The
RAD51 expressed in the E. coli strain was puriﬁed by a
four-step method, as described previously (22). In this
method, the puriﬁed RAD51 lacked the hexahistidine
tag. Human RPA was produced in E. coli cells, and was
prepared according to the published protocol (23). Protein
concentrations were determined using the Bradford
method (24), with bovine serum albumin as the standard
protein.
DNAs
The fX174 phage ssDNA and dsDNA used in the
DNA-binding and strand-exchange assays were purchased
from New England Biolabs (Ipswich, MA, USA). All of
the DNA concentrations are expressed in moles of
nucleotides.
Assay for strand exchange
The fX174 circular ssDNA (20mM) was incubated with
RAD51 (6mM) in the presence of a chemical compound
at 378C for 10min, in 10ml of 26mM HEPES buﬀer
(pH 7.5), containing 45mM NaCl, 0.03mM EDTA,
0.6mM 2-mercaptoethanol, 3% glycerol, 1mM MgCl2,
1mM DTT, 1mM ATP, 0.1mg/ml bovine serum albumin,
2mM CaCl2, 20mM creatine phosphate and 75mg/ml
creatine kinase. After this incubation, 2mM RPA was
added to the reaction mixture, which was incubated at
378C for 10min. The reactions were then initiated by the
addition of 20mM fX174 linear dsDNA, and were con-
tinued for 60min. The reactions were stopped by the addi-
tion of 0.1% SDS and 1.97mg/ml proteinase K (Roche
Applied Science, Basel, Switzerland), and were further
incubated at 378C for 20min. After adding 6-fold loading
dye, the deproteinized reaction products were separated
by 1% agarose gel electrophoresis in 1  TAE buﬀer at
3.3V/cm for 4h. The products were visualized by SYBR
Gold (Invitrogen, Carlsbad, CA, USA) staining. When the
reactions were performed with the
32P-labeled dsDNA, the
gels were dried, exposed to an imaging plate and visualized
using an FLA-7000 imaging analyzer (Fujiﬁlm, Tokyo,
Japan).
The D-loop formation assay
To prevent the dsDNA substrates from undergoing irre-
versible denaturation, superhelical dsDNA (pB5Sarray
DNA), which contained 11 repeats of a sea urchin 5S
rRNA gene (207-bp fragment) within the pBlueScript II
SK(+) vector, was prepared by a method avoiding
alkaline treatment of the cells harboring the plasmid
DNA (25,26). For the ssDNA substrate, the following
high-performance liquid chromatography (HPLC)-
puriﬁed oligonucleotide was used: 50-mer, 50-GGA ATT
CGG TAT TCC CAG GCG GTC TCC CAT CCA AGT
ACT AAC CGA GCC CT-30. The 50-end of the oligonu-
cleotide was labeled with T4 polynucleotide kinase
(New England Biolabs, Ipswich, MA, USA) in the pres-
ence of [g-
32P]ATP. RAD51 (0.1mM) was incubated
with the indicated amount of DIDS at 378C for 5min,
in 7ml of reaction buﬀer, containing 22mM HEPES–
NaOH (pH 7.5), 15mM NaCl, 0.01mM EDTA, 0.2mM
2-mercaptoethanol, 1% glycerol, 1mM MgCl2,1 m M
DTT, 2mM AMPPNP and 0.1mg/ml BSA. The
32P-labeled 50-mer oligonucleotide (1mM) was then
added, and the samples were further incubated at 378C
for 5min. The pB5Sarray superhelical dsDNA (10mM)
was added along with 9mM MgCl2 to initiate the homo-
logous-pairing reaction. The reactions were continued at
378C for 30min, and were stopped by the addition of
0.1% SDS and 1.97mg/ml proteinase K (Roche Applied
Science). After deproteinization at 378C for 15min, the
reaction products were separated by 1% agarose gel elec-
trophoresis in 1  TAE buﬀer at 3.3V/cm for 2.5h. The
gels were dried, exposed to an imaging plate, and visua-
lized using an FLA-7000 imaging analyzer (Fujiﬁlm).
ATPase activity
RAD51 (6mM) was incubated with 1mM ATP (Roche
Applied Science) in 26mM HEPES buﬀer (pH 7.5), con-
taining 45mM NaCl, 1mM MgCl2, 3% glycerol, 0.03mM
EDTA, 0.6mM 2-mercaptoethanol, 1mM dithiothreitol
and 0.1mg/ml bovine serum albumin, in the presence or
absence of ssDNA. In the ssDNA-dependent reaction, the
fX174 circular ssDNA (40mM) was used as the substrate.
The reaction was performed at 378C. After a 10min pre-
incubation in the absence of ATP, the reaction was
initiated by adding 1mM ATP. At each indicated time,
a2 0 ml aliquot of the reaction mixture was removed and
mixed with 30ml of 100mM EDTA, to quench the reac-
tion. The amount of inorganic phosphate released was
determined by a colorimetric assay. Brieﬂy, a 500ml ali-
quot of a malachite green solution [0.034%(w/v) malachite
green oxalate, 1.05%(w/v) hexaammonium heptamolyb-
date tetrahydrate, and 0.1%(w/v) polyvinyl alcohol
in 1M HCl] was mixed with 50ml of sample solution
(i.e. the reaction mixture quenched with EDTA). After
1min, 50ml of 34%(w/v) sodium citrate dihydrate was
added to stop further color development. The absorbance
3368 Nucleic Acids Research, 2009, Vol. 37,No. 10at 655nm was measured with a 96-well micro plate reader
(Bio-Rad Laboratories, Hercules, CA, USA). A 1mg/ml
phosphate ion standard solution (Wako Pure Chemical
Industries, Osaka, Japan) was used to prepare the phos-
phate standards.
Assays for DNA binding
The fX174 circular ssDNA (40mM) or fX174 linear
dsDNA (10mM) was mixed with RAD51 in 10mlo f
24mM HEPES buﬀer (pH 7.5), containing 30mM
NaCl, 1mM MgCl2, 2% glycerol, 0.02mM EDTA,
0.4mM 2-mercaptoethanol, 1mM dithiothreitol, 0.1mg/
ml bovine serum albumin, 1mM ATP, 20mM creatine
phosphate, 75mg/ml creatine kinase and 2mM CaCl2.
The reaction mixtures were incubated at 378C for
15min, and were then analyzed by 0.8% agarose gel elec-
trophoresis in 1  TAE buﬀer (40mM Tris–acetate and
1mM EDTA) at 3.3V/cm for 2.5h. The bands were visua-
lized by ethidium bromide staining. For the RPA-ssDNA
binding assay, the fX174 circular ssDNA (40mM) was
mixed with RPA in 10ml of 20mM HEPES buﬀer
(pH 7.5), containing 10mM KCl, 1mM MgCl2, 2% gly-
cerol, 1.2mM dithiothreitol and 0.1mg/ml bovine serum
albumin.
Gel filtration
RAD51 (45mg) was incubated with 100mM of DIDS,
and the samples were analyzed by Superdex 200 HR
10/30 (GE Healthcare Biosciences, Uppsala, Sweden) gel
ﬁltration chromatography. The elution buﬀer contained
20mM HEPES–NaOH (pH 7.5), 150mM NaCl, 0.1mM
EDTA, 2mM 2-mercaptoethanol and 10% glycerol, and
the ﬂow rate was 0.5ml/min.
Surface plasmon resonance analysis
The interaction between RAD51 and DIDS was detected
with a Biacore T100 surface plasmon resonance biosensor
(GE Healthcare Biosciences). RAD51 was immobilized to
the sensor surface of a CM-5 sensor chip by the random
amine coupling method. Surface activation with N-hydro-
xysuccinimide and N-ethyl-N0-(3-dimethylaminopropyl)
carbodiimide (GE Healthcare Biosciences) was followed
by an injection of RAD51 (30mg/ml), which was diluted
in 10mM NaOAc (pH 4.7) prior to injection. Unliganded
sites on the chip were then blocked with ethanolamine.
A 100ml (10min) injection of RAD51 resulted in the
immobilization of about 20000 response units (RU) of
RAD51. Subsequently, the interaction experiments were
carried out in 20mM HEPES buﬀer (pH 7.5) containing
1mM dithiothreitol, at a ﬂow rate of 30ml/min. A 30ml
(1min) aliquot of each of the diﬀerent concentrations of
DIDS (1.25, 2.5, 5, 10, 20mM) was injected onto the chip
sequentially, without regeneration (kinetic titration). The
baseline response of the non-treated surface of the chip
was subtracted from the response obtained from the
RAD51 surface. Kinetic parameters, such as ka and kd,
were calculated with the Biacore T100 Evaluation
Software (GE Healthcare Biosciences).
RESULTS
DIDS is a potential inhibitor of RAD51-mediated
strand exchange
To identify chemical compounds that aﬀect the recombi-
nase activity of RAD51, we employed the strand-exchange
assay. In this assay, fX174 phage circular ssDNA (5386
bases) and linearized fX174 dsDNA (5386 base pairs)
were used as DNA substrates, and the reactions were con-
ducted in the presence of RPA. In this combination of
DNA substrates, both intermediate (joint molecule; JM)
and complete strand-exchange products (nicked circular;
NC) were potentially detectable (Figure 1A). However,
under the reaction conditions used in this study, only
the JM product was detected, because 5% methanol
(as a solvent for chemical compounds) and low concentra-
tions of salt, which are not optimal for the reaction,
were present in the reaction mixture (Figure 1B).
We then performed the RAD51-mediated strand
exchange in the presence of each of 185 chemical com-
pounds, which were selected as potential antitumor chem-
ical compounds by the program of Scientiﬁc Research on
Priority Areas, Cancer, Japan (Supplementary Table 1).
As shown in Figure 2A, most of the chemical compounds
did not aﬀect the RAD51-mediated strand exchange;
however, we found that DIDS (Figure 2A, #137 and B)
was a potential inhibitor for the RAD51-mediated strand
exchange. Careful titration experiments conﬁrmed that
DIDS actually inhibited the RAD51-mediated strand
exchange (Figure 3A and B). DIDS also inhibited the
Figure 1. The strand-exchange assay with human RAD51. (A) A sche-
matic diagram of the strand-exchange assay. (B) The strand exchange
activity of RAD51 under the three diﬀerent conditions. The fX174
circular ssDNA (20mM) was incubated with RAD51 (6mM) at 378C
for 10min. After this incubation, 2mM RPA was added to the reaction
mixture, which was incubated at 378C for 10min. The reactions were
then initiated by the addition of 20mM fX174 linear dsDNA. The
DNA products were then deproteinized, and were separated by 1%
agarose gel electrophoresis in 1  TAE buﬀer at 3.3V/cm for 4h. The
products were visualized by SYBR Gold (Invitrogen) staining. Joint
molecules and nicked circular DNA are indicated by jm and nc, respec-
tively. Lane 1 indicates a negative control experiment without RAD51.
Lanes 2 and 3 indicate experiments with RAD51 in the absence and
presence of 0.2M KCl, respectively. Lane 4 indicates an experiment
with 5% methanol in the absence of 0.2M KCl.
Nucleic Acids Research, 2009,Vol.37, No. 10 3369RAD51-mediated strand exchange under the conditions
with 0.2M KCl, which signiﬁcantly stimulates the strand
exchange (Figure 3C and D).
We next tested whether the reaction order of the
DIDS addition aﬀected the strand-exchange inhibition.
Time-course experiments were performed. Since we used
32P-labeled dsDNA in this assay, the JM products and
dsDNA were detected using an FLA-7000 imaging analy-
zer (Fujiﬁlm). As shown in Figure 4A and B, DIDS sig-
niﬁcantly inhibited the RAD51-mediated strand exchange,
when it was added before the RAD51 was incubated with
the ssDNA. DIDS moderately inhibited the strand
exchange, when it was added after the RAD51was incu-
bated with the ssDNA (just before RPA addition)
(Figure 4C and D). Modest, but clear, inhibition was
observed when DIDS was added before dsDNA (after
RPA addition) (Figure 4E and F). Therefore, DIDS
actually inhibits the RAD51-mediated strand exchange
in various reaction orders, although the inhibition eﬃcien-
cies depend on the reaction order.
DIDS inhibits homologous pairing by RAD51
We then tested whether DIDS inhibits homologous
pairing by RAD51, because the homologous-pairing step
needs to occur just before strand exchange. To do so,
we performed the D-loop formation assay. In this assay,
a
32P-labeled ssDNA 50-mer and superhelical dsDNA
were used as substrates (Figure 5A), and the reactions
were performed in the absence of RPA. As shown in
Figure 5B and C, DIDS inhibited the RAD51-mediated
D-loop formation in a concentration-dependent manner.
These results indicated that DIDS inhibits homologous
pairing, as well as strand exchange, by RAD51 in vitro.
DIDS directly binds to RAD51
To determine whether DIDS directly binds to RAD51, we
performed a surface plasmon resonance (SPR) analysis.
As shown in Figure 6A, DIDS directly interacted with
the RAD51-conjugated sensor chip. The association
rate constant (ka) and the dissociation rate constant
Figure 2. The strand-exchange assay in the presence of chemical compounds. (A) Each chemical compound (10mM, lanes 1–185) was incubated with
RAD51 (6mM), and the strand-exchange reaction was performed under the conditions containing 5% methanol at 378C for 1h with 20mM ssDNA,
20mM dsDNA and 2mM RPA. Lanes C, R and M indicate negative control reactions without RAD51, complete reactions and complete reactions
with 5% methanol, respectively. The chemical compounds are listed in Supplementary Table 1. (B) Structure of 4,40-diisothiocyanostilbene-2,20-
disulfonic acid (DIDS).
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 1, respectively. Therefore,
the KD value of the RAD51–DIDS interaction is 2mM.
The DIDS binding did not disrupt the RAD51 multimer,
which eluted near the void volume from the Superdex
200 gel ﬁltration column (Figure 6B). This RAD51 multi-
mer is known to be disrupted by the BRC4 peptide (27),
which binds to the RAD51–RAD51 interface (28–30).
Therefore, DIDS may bind a diﬀerent region than the
BRC4-binding surface of RAD51.
DIDS inhibits the RAD51-DNA binding
We then examined whether DIDS aﬀected the
RAD51-DNA binding. Consistent with the results from
the homologous-pairing and strand-exchange assays,
DIDS signiﬁcantly inhibited the ssDNA binding and
dsDNA binding by RAD51 (Figure 7A and B). A 1mM
concentration of DIDS, which moderately inhibited
strand exchange (Figure 3A and B), also moderately
inhibited the RAD51-DNA binding, especially for the
dsDNA (Figure 7B, lane 6). In addition, 10mM DIDS,
which signiﬁcantly inhibited strand exchange (Figure 3A
and B), also signiﬁcantly inhibited both RAD51-ssDNA
binding and RAD51-dsDNA binding (Figure 7A, lane 6
and B, lane 7). These inhibitory eﬀects of DIDS on the
RAD51-DNA binding did not depend on the presence of
ATP or its analogs, AMPPNP and ATPgS (Figure 7C and
D). In contrast, DIDS did not inhibit the RPA-ssDNA
binding in the presence of 0.1–20mM DIDS (Figure 7E).
These results strongly suggested that DIDS inhibits
the RAD51-mediated strand exchange by preventing
RAD51-DNA binding, and not by inhibiting RPA-
ssDNA binding, although RPA is required for the eﬃcient
promotion of the RAD51-mediated strand exchange.
DIDS stimulates the ATP hydrolyzing activity of RAD51
in the absence of DNA
RAD51 hydrolyzes ATP in the presence of ssDNA or
higher concentrations of salt (1.5M NaCl) (31). In con-
trast, RAD51 does not eﬃciently hydrolyze ATP without
DNA under low salt conditions. Interestingly, under the
conditions without DNA and high salt, 10mM DIDS sti-
mulated ATP hydrolysis by RAD51 (Figure 8A). This
may imply that DIDS binds near the DNA binding site
of RAD51 and stimulates the ATPase activity. If so, then
the DIDS may compete with ssDNA for RAD51 binding,
and may inhibit the ssDNA-dependent ATP hydrolysis
by RAD51, once the ATP hydrolyzing reaction has
commenced. As shown in Figure 8B, the progress of the
ssDNA-dependent ATP hydrolysis reaction by RAD51
was clearly inhibited just after the addition of DIDS
(30min). Therefore, DIDS may bind to a region close to
the DNA binding site(s) of RAD51, and directly compete
with DNA for RAD51 binding.
DISCUSSION
Increased expression of RAD51 has been reported
in immortalized and tumor cells (32), and chromosome
rearrangements, probably resulting from the enhanced
homologous recombination, are found in these cells.
Consistently, the overexpression of RAD51 enhances cell
growth and gene targeting in mouse hybridoma cells (33),
and promotes aneuploidy and multiple chromosomal
rearrangements in mouse embryonic stem cells (34).
Figure 3. DIDS eﬃciently inhibits RAD51-mediated strand exchange.
(A) DIDS titration experiments in the absence of 0.2M KCl. The
fX174 circular ssDNA (20mM) was incubated with RAD51 (6mM)
in the presence of DIDS at 378C for 10min. After this incubation,
2mM RPA was added to the reaction mixture, which was incubated
at 378C for 10min. The reactions were then initiated by the addition of
20mM fX174 linear dsDNA. The DNA products were then deprotei-
nized, and were separated by 1% agarose gel electrophoresis in 1 
TAE buﬀer at 3.3V/cm for 4h. The products were visualized by
SYBR Gold (Invitrogen) staining. Joint molecule is indicated by jm.
Lane 1 indicates a negative control experiment without RAD51. Lane 2
indicates an experiment with RAD51 and 5% methanol in the absence
of DIDS. DIDS concentrations were 0.01mM (lane 3), 0.1mM (lane 4),
1 mM (lane 5) and 10mM (lane 6). Lane 7 indicates an experiment with
10mM DIDS in the absence of RAD51. (B) Graphic representation of
the experiments shown in (A). The band intensities of the jm product
were quantiﬁed as the peak volumes of densitometric scans. The
jm peak volumes relative to that in the reaction without DIDS
(A, lane 2) were plotted against the DIDS concentration. (C) The
strand-exchange assay in the presence of 0.2M KCl. Lane 1 indicates
a negative control experiment without RAD51. Lanes 2 and 3 indicate
control experiments without DIDS with RAD51 in the absence
and presence of 5% methanol, respectively. DIDS concentrations
were 0.01mM (lane 4), 0.1mM (lane 5), 1mM (lane 6) and 10mM
(lane 7). Lane 8 indicates an experiment with 10mM DIDS in the
absence of RAD51. (D) Graphic representation of the experiments
shown in (C). The band intensities of the jm products were quantiﬁed
as the peak volumes of densitometric scans. The jm peak volumes
relative to that in the reaction without DIDS (C, lane 3) were plotted
against the DIDS concentration.
Nucleic Acids Research, 2009,Vol.37, No. 10 3371RAD51 overexpression also contributes to chemoresis-
tance in human soft tissue sarcoma cells (35). BRCA1 is
involved in the HRR pathway. Intriguingly, RAD51 over-
expression bypasses BRCA1 function in BRCA1-deﬁcient
cells, and up-regulation of RAD51 was found in BRCA1-
deﬁcient tumors (36). In addition, constitutive phosphor-
ylation of the RAD51-Tyr315 residue in leukemia cells
enhanced the recombination activity, which induces chro-
mosomal translocation (16). These data strongly suggest
that an elevated RAD51 level and/or activity causes
genome instability and tumor progression.
To identify chemical compounds that suppress the
recombinase activity of RAD51, we performed the
RAD51-mediated strand-exchange assay in the presence
of each of 185 chemical compounds, which were selected
as potential antitumor chemical compounds by the pro-
gram of Scientiﬁc Research on Priority Areas, Cancer,
Japan. We found that DIDS signiﬁcantly inhibits both
homologous pairing and strand exchange by RAD51
in vitro, probably by inhibiting the DNA-binding activity
of RAD51. The BRC4 polypeptide derived from BRCA2
is known to inhibit DNA binding by RAD51 (28).
This polypeptide directly binds to RAD51 at the
monomer–monomer interface of the RAD51 ﬁlament,
and disassembles the ﬁlament (27–30). Our SPR analysis
revealed that DIDS also directly binds to RAD51. In con-
trast to the BRC4 polypeptide, a gel ﬁltration analysis
revealed that DIDS did not disrupt the RAD51 multimer,
which is known to be disrupted by the BRC4 polypeptide
(27). Therefore, DIDS may bind to a diﬀerent RAD51
surface from the BRC4-binding region.
Our results presented here suggest that DIDS may bind
near the DNA binding sites of RAD51. In addition, we
found that DIDS inhibits the RAD51-dsDNA binding
more eﬃciently than the RAD51-ssDNA binding. This
fact implies that DIDS may bind to the secondary DNA
binding site speciﬁc for dsDNA within the RAD51 ﬁla-
ment (37–40). Another possibility is that DIDS may
bind to the dsDNA-binding path, which may function to
guide DNA into the RAD51 ﬁlament. Previously, we and
others proposed that the N-terminal domain of RAD51
(as well as that of a meiosis-speciﬁc homologue, DMC1)
constitutes such a dsDNA-binding path (37–42). We
found that 50% inhibition of the RAD51-mediated
Figure 4. Eﬀects of the DIDS reaction order on RAD51-mediated strand exchange. The fX174 circular ssDNA (20mM) was incubated with RAD51
(6mM) at 378C for 10min. After this incubation, 2mM RPA was added to the reaction mixture, which was incubated at 378C for 10min. The
reactions were then initiated by the addition of 20mM fX174 linear dsDNA containing 2mM
32P-labeled fX174 linear dsDNA, in the absence of
0.2M KCl. The reactions were stopped and deproteinized at the indicated times, and the products were separated by 1% agarose gel electrophoresis
in 1  TAE buﬀer at 3.3V/cm for 4h. The jm products and dsDNA labeled by
32P were visualized and quantiﬁed using an FLA-7000 imaging
analyzer (Fujiﬁlm). (A) RAD51 was incubated with DIDS (10mM) at 378C for 10min. After the addition of the fX174 circular ssDNA, RPA was
added to the reaction mixture. The fX174 linear dsDNA was then added to initiate the reaction. The reactions were continued for the indicated
times. Lanes 1–4 indicate positive control experiments with RAD51 and 5% methanol. Lanes 5–8 indicate experiments with RAD51 and DIDS (and
5% methanol). Reaction times were 0min (lanes 1 and 5), 30min (lanes 2 and 6), 60min (lanes 3 and 7) and 90min (lanes 4 and 8). (B) Graphic
representation of the experiments shown in (A). Closed and open circles indicate experiments with and without DIDS, respectively. (C) RAD51 was
incubated with the fX174 circular ssDNA at 378C for 10min. After this incubation, DIDS (10mM) was added, followed by the addition of RPA.
The fX174 linear dsDNA was then added to initiate the reaction. (D) Graphic representation of the experiments shown in (C). Closed and open
circles indicate experiments with and without DIDS, respectively. (E) RAD51 was incubated with the fX174 circular ssDNA at 378C for 10min, and
RPA was added. DIDS was added, and then fX174 linear dsDNA was added to initiate the reaction. (F) Graphic representation of the experiments
shown in (E). Closed and open circles indicate experiments with and without DIDS, respectively.
3372 Nucleic Acids Research, 2009, Vol. 37,No. 10strand exchange was observed at a ratio of about 1–2mM
DIDS to 6mM RAD51, suggesting the binding of approx-
imately 1 DIDS per turn of the RAD51 ﬁlament.
Therefore, DIDS may inhibit the dsDNA binding to the
RAD51 ﬁlament on the dsDNA-binding path that runs
between two consecutive N-terminal domains in the ﬁla-
ment structure. Further structural studies will be required
to understand the molecular mechanism of the DIDS-
mediated alteration of the RAD51 activities.
DIDS reportedly binds to the outer cell membrane sur-
face, and inhibits Cl
  channels (43). However, no DIDS
function in the nucleus has been reported, thus far. We
conﬁrmed that DIDS was eﬃciently imported into the
nuclei of human cultured cells (H.S. and S.T. unpublished
results). Actually, DIDS was toxic for the cultured
cells (H.S. and S.T. unpublished results), and thus it was
diﬃcult to evaluate the contribution of the DIDS-
mediated RAD51 suppression, because of its cytotoxicity.
Therefore, DIDS may be a potential lead compound for
developing RAD51-speciﬁc anticancer drugs. Jayathilaka
et al. (44) reported that 3-[(benzylamino)sulfonyl]-
4-bromo-N-(4-bromophenyl)benzamide (RS-1) stimulated
RAD51 activity. RS-1 also directly binds to RAD51, but,
in contrast to DIDS, it stabilizes the RAD51-DNA bind-
ing. These two chemical compounds, DIDS and RS-1,
which have opposite eﬀects on the RAD51 activity, may
have broad potential applications in both research and
medical settings.
Figure 6. DIDS binds to RAD51 without interfering the RAD51 oligomerization. (A) SPR analysis. The RAD51-conjugated sensorchip was used.
Sensorgram of a kinetic titration analysis between RAD51 and DIDS presented with a solid line. The DIDS concentrations were 1.25, 2.5, 5, 10 and
20mM. DIDS (30ml) was applied to the chip sequentially without regeneration. Kinetic parameters were obtained by curve ﬁtting with a red line.
(B) Gel ﬁltration analysis. The left panel indicates the elution proﬁle of RAD51 from the Superdex 200 column. The right panel indicates the elution
proﬁle of RAD51 previously incubated with 10mM DIDS. The peak intensity of the RAD51–DIDS complex (right panel) was higher than that of
RAD51 alone (left panel), because DIDS contains two aromatic rings.
Figure 5. DIDS inhibits homologous pairing by RAD51. (A) The
D-loop formation assay. Asterisks indicate the
32P-labeled end of the
ssDNA 50-mer. (B) The reactions were conducted with 0.1mM RAD51
in the presence of increasing amounts of DIDS. Lanes 1 and 6 indicate
negative control experiments without and with 10mM DIDS in the
absence of RAD51, respectively. Lane 2 indicates a positive control
experiment with RAD51 in the presence of 5% methanol. Lanes 3–5
indicate experiments with RAD51 and DIDS. The DIDS concentra-
tions were 0mM (lanes 1 and 2), 0.1mM (lane 3), 1mM (lane 4) and
10mM (lanes 5 and 6). (C) Graphic representation of the experiments
shown in (B).
Nucleic Acids Research, 2009,Vol.37, No. 10 3373Figure 7. DIDS inhibits DNA binding by RAD51. (A) The ssDNA-binding experiments in the presence of ATP. The fX174 circular ssDNA (40mM)
was incubated with RAD51 (2mM) in the presence of DIDS at 378C for 15min. The samples were analyzed by 0.8% agarose gel electrophoresis in 1 
TAE buﬀer. The bands were visualized by ethidium bromide staining. Lane 1 indicates a negative control experiment without RAD51. Lane 2 indicates
an experiment with RAD51 alone. Lane 3 indicates an experiment with RAD51 and 5% methanol. DIDS concentrations were 0.1mM (lane 4), 1mM
(lane 5), 10mM (lane 6) and 20mM (lane 7). Lane 8 indicates an experiment with 20mM DIDS in the absence of RAD51. (B) The dsDNA-binding
experiments in the presence of ATP. The linear fX174 dsDNA (10mM) was incubated with RAD51 (1mM) in the presence of DIDS at 378C for 15min.
Lane 1 indicates a negative control experiment without RAD51. Lane 2 indicates an experiment with RAD51 alone. Lane 3 indicates an experiment with
RAD51 and 5% methanol. DIDS concentrations were 0.01mM (lane 4), 0.1mM (lane 5), 1mM (lane 6) and 10mM (lane 7). Lane 8 indicates an
experiment with 10mM DIDS in the absence of RAD51. (C) The ssDNA-binding experiments in the presence of ATP, AMPPNP and ATPgS. The
fX174 circular ssDNA (40mM) was incubated with RAD51 (2mM) at 378C for 15min. Lanes 1–4, lanes 5–8 and lanes 9–12 represent experiments with
ATP, AMPPNP and ATPgS, respectively. Lanes 1, 5 and 9 indicate negative control experiments without RAD51. Lanes 2, 6 and 10 indicate
experiments with RAD51 alone. Lanes 3, 7 and 11 indicate experiments with RAD51 and 5% methanol. Lanes 4, 8 and 12 indicate experiments
with RAD51 and DIDS (20mM). (D) The dsDNA-binding experiments in the presence of ATP, AMPPNP and ATPgS. The linear fX174 dsDNA
(10mM) was incubated with RAD51 (1mM) in the presence of DIDS at 378C for 15min. Lanes correspond to those in (C). The DIDS concentration was
10mM. (E) Eﬀect of DIDS on the ssDNA binding of RPA. The fX174 circular ssDNA (40mM) was incubated with RPA (0.5mM) in the presence of
DIDS at 378C for 15min. Lanes 1 and 8 indicate negative control experiments without RPA. Lanes 2 and 3 indicate experiments with RPA in the absence
and presence of 5% methanol, respectively. The DIDS concentrations were 0.1mM (lane 4), 1mM (lane 5), 10mM (lane 6) and 20mM (lanes 7 and 8). (F)
The ssDNA-binding and dsDNA-binding experiments with RAD51 were performed in the presence of methanol. Lanes 1–6 and lanes 7–12 indicate
experiments with ssDNA and dsDNA, respectively. Lanes 1, 6, 7 and 12 are negative controls without RAD51, and lanes 2 and 8 are positive controls
with RAD51 in the absence of methanol. Methanol concentrations were 2.5% (lanes 3 and 9), 5% (lanes 4 and 10) and 10% (lanes 5, 6, 11 and 12).
Figure 8. RAD51-mediated ATP hydrolysis with DIDS. (A) Open and closed circles indicate positive and negative control experiments without
DIDS, in the presence and absence of ssDNA (40mM), respectively. Closed squares indicate the experiments with DIDS (10mM) in the absence of
ssDNA. The averages of three independent experiments are represented with standard deviation values. (B) DIDS (20mM) was added at 30min after
the ATP hydrolyzing reaction was initiated. Reactions were conducted at 378C in the presence of ssDNA (40mM). Closed and open circles indicate
experiments with 5% methanol and DIDS, respectively. (C) Five percent methanol did not aﬀect the ssDNA-dependent ATP hydrolysis by RAD51.
Closed and open circles indicate experiments without and with 5% methanol, respectively.
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